Stocks TelegraphStocks Telegraph
Stock Ideas

BDRX Financial Statements and Analysis

NASDAQ : BDRX

Biodexa Pharmaceuticals

$0.87
0.2593+42.23%
At Close 4:00 PM

FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateJun 30, 2025Jun 30, 2024Mar 31, 2024
reported currencyGBPGBPGBP
calendar year202520242024
periodQ2Q2Q1
revenue000
cost of revenue1.665M2.189M1.095M
gross profit-1.665M-2.189M-1.095M
gross profit ratio000
research and development expenses1.665M2.189M1.095M
general and administrative expenses2.378M2.034M1.017M
selling and marketing expenses000
selling general and administrative expenses2.378M2.034M1.017M
other expenses-1.692M-2.189M-1.094M
operating expenses2.351M2.034M1.017M
cost and expenses4.016M4.223M2.112M
interest income000
interest expense100.00K00
depreciation and amortization71.00K68.00K34.00K
ebitda-3.945M-4.155M-2.078M
ebitda ratio000
operating income-4.016M-4.223M-2.112M
operating income ratio000
total other income expenses net45.00K790.00K395.00K
income before tax-3.971M-3.433M-1.717M
income before tax ratio000
income tax expense165.00K125.00K62.50K
net income-3.806M-3.308M-1.654M
net income ratio000
eps-150.60K-10.08-5.04
eps diluted-150.60K-10.08-5.04
weighted average shs out25.00328.08K328.08K
weighted average shs out dil25.00328.08K328.08K
Graph

Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateJun 30, 2025Jun 30, 2024Mar 31, 2024
reported currencyGBPGBPGBP
calendar year202520242024
periodQ2Q2Q1
cash and cash equivalents4.036M5.055M5.055M
short term investments000
cash and short term investments4.036M5.055M5.055M
net receivables4.494M1.922M1.922M
inventory000
other current assets462.00K547.00K547.00K
total current assets8.992M7.524M7.524M
property plant equipment net187.00K436.00K436.00K
goodwill000
intangible assets5.645M6.008M6.008M
goodwill and intangible assets5.645M6.008M6.008M
long term investments000
tax assets000
other non current assets000
total non current assets5.832M6.444M6.444M
other assets000
total assets14.824M13.968M13.968M
account payables1.414M1.689M1.689M
short term debt501.00K174.00K174.00K
tax payables000
deferred revenue000
other current liabilities564.00K1.618M1.618M
total current liabilities2.479M3.481M3.481M
long term debt0208.00K208.00K
deferred revenue non current000
deferred tax liabilities non current000
other non current liabilities909.00K1.552M1.552M
total non current liabilities909.00K1.76M1.76M
other liabilities000
capital lease obligations0382.00K382.00K
total liabilities3.388M5.241M5.241M
preferred stock0091.242M
common stock61.561K3.626M3.626M
retained earnings-154.133M-147.881M-147.881M
accumulated other comprehensive income loss67.773M61.74M61.74M
other total stockholders equity97.734M91.242M91.242M
total stockholders equity11.436M8.727M8.727M
total equity11.436M8.727M8.727M
total liabilities and stockholders equity14.824M13.968M13.968M
minority interest000
total investments000
total debt501.00K382.00K0
net debt-3.535M-4.673M-5.055M
Graph

Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateJun 30, 2025Jun 30, 2024Mar 31, 2024
reported currencyGBPGBPGBP
calendar year202520242024
periodQ2Q2Q1
deferred income tax000
stock based compensation97.00K75.00K75.00K
change in working capital2.047M-649.00K-649.00K
accounts receivables2.047M-649.00K-649.00K
inventory000
accounts payables000
other working capital000
other non cash items-1.782M-243.50K-243.50K
net cash provided by operating activities-3.304M-2.404M-2.404M
investments in property plant and equipment-2.00K00
acquisitions net000
purchases of investments000
sales maturities of investments000
other investing activites-337.00K-377.00K-377.00K
net cash used for investing activites-339.00K-377.00K-377.00K
debt repayment-95.00K00
common stock issued000
common stock repurchased000
dividends paid000
other financing activites6.105M2.323M2.323M
net cash used provided by financing activities6.01M2.323M2.323M
effect of forex changes on cash000
net change in cash4.036M-458.00K-458.00K
cash at end of period4.036M-458.00K-458.00K
cash at beginning of period000
operating cashflow-3.304M-2.404M-2.404M
capital expenditure-2.00K00
free cash flow-3.306M-2.404M-2.404M
Graph

Frequently Asked Questions

How did Biodexa Pharmaceuticals Plc do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, BDRX generated $0.00 in revenue last quarter, while its costs came in at $1.67M.
Last quarter, how much Gross Profit did Biodexa Pharmaceuticals Plc report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Biodexa Pharmaceuticals Plc reported a -$1.67M Gross Profit for the quarter ended Jun 30, 2025.
Have BDRX's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. BDRX incurred $2.35M worth of Operating Expenses, while it generated -$4.02M worth of Operating Income.
How much Net Income has BDRX posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Biodexa Pharmaceuticals Plc, the company generated -$3.81M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Biodexa Pharmaceuticals Plc have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Biodexa Pharmaceuticals Plc as of the end of the last quarter was $4.04M.
What are BDRX's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, BDRX had Total Net Receivables of $4.49M.
In terms of Total Assets and Current Assets, where did Biodexa Pharmaceuticals Plc stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of BDRX were $8.99M, while the Total Assets stand at $14.82M.
As of the last quarter, how much Total Debt did Biodexa Pharmaceuticals Plc have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of BDRX's debt was $501.00K at the end of the last quarter.
What were BDRX's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, BDRX reported total liabilities of $3.39M.
How much did BDRX's Working Capital change over the last quarter?
Working Capital Change for BDRX was $2.05M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
BDRX generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. BDRX generated -$3.30M of Cash from Operating Activities during its recently reported quarter.
What was BDRX's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. BDRX reported a $4.04M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph